Medicine company that develops biologic products for the broad field of regenerative medicine
Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.
The Company’s portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians.
Visit website: https://www.mesoblast.com/
Mesoblast develops an injection with stem cells having anti-inflammatory effect to treat heart attack
Freethink - 12-Mar-2023
A new weapon that could give doctors an entirely new way to treat heart failureRead more...
Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021
Longevity Technology - 25-Feb-2022
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.Read more...